These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Harris MG; Coleman SG; Faulds D; Chrisp P Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188 [TBL] [Abstract][Full Text] [Related]
25. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723 [TBL] [Abstract][Full Text] [Related]
26. [Respiratory side-effects of drugs]. van der Drift MA; Kaajan JP Ned Tijdschr Geneeskd; 2002 Jan; 146(4):145-50. PubMed ID: 11845561 [TBL] [Abstract][Full Text] [Related]
27. [Pulmonary toxicity of nilutamide (Anandron). Cooperative evaluation of French Regional Pharmacovigilance Centers]. Jonville AP; Diot E; Dutertre JP; Autret E Therapie; 1992; 47(5):393-7. PubMed ID: 1299978 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer. Migliari R; Scarpa RM; Campus G; De Lisa A; Zucca I; D'Atri M; Serra A; Usai E Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):147-53. PubMed ID: 1830407 [TBL] [Abstract][Full Text] [Related]
31. [Acute depressive syndrome possibly due to nilutamide (Anandron) treatment]. Maroy B; Pitrou P Therapie; 1997; 52(1):79-81. PubMed ID: 9183930 [No Abstract] [Full Text] [Related]
32. [Complete androgen blockage in the treatment of metastatic prostate cancer]. Matzkin H; Braf Z Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104 [No Abstract] [Full Text] [Related]
33. [Chemotherapy in hormone refractory prostatic carcinoma]. Biedermann B; Pless M; Herrmann R Dtsch Med Wochenschr; 1999 Jul; 124(28-29):874-9. PubMed ID: 10432951 [No Abstract] [Full Text] [Related]
34. Long-term impact of androgen-deprivation therapy on physical function and quality of life. Alibhai SM; Breunis H; Timilshina N; Naglie G; Tannock I; Krahn M; Warde P; Fleshner NE; Canning SD; Tomlinson G Cancer; 2015 Jul; 121(14):2350-7. PubMed ID: 25809861 [TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal. Laires PA; Ejzykowicz F; Hsu TY; Ambegaonkar B; Davies G J Med Econ; 2015; 18(8):565-72. PubMed ID: 25788039 [TBL] [Abstract][Full Text] [Related]
36. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo. Brisset JM; Boccon-Gibod L; Botto H; Camey M; Cariou G; Duclos JM; Duval F; Gontiès D; Jorest R; Lamy L Prog Clin Biol Res; 1987; 243A():411-22. PubMed ID: 3309973 [No Abstract] [Full Text] [Related]
37. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate]. Matveev BP; Bukharkin BV Vopr Onkol; 1998; 44(5):537-40. PubMed ID: 9884710 [TBL] [Abstract][Full Text] [Related]
38. A review of the use of histrelin acetate in the treatment of prostate cancer. Crawford ED BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148 [No Abstract] [Full Text] [Related]
39. The place and the results of monotherapy. Bonnet P Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120 [No Abstract] [Full Text] [Related]
40. The role of intermittent androgen deprivation in prostate cancer. Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]